Vascular surgeons perform procedures interventional cardiologists and interventional radiologists do not do—so why not make sure they are part of every heart team conversation?
The Center for Medicare and Medicaid Innovation (CMMI) has tested nearly 40 APMs, of which only two turned out to be successful, which does not bode well for meeting a 2030 deadline to transition to value-based payments.
Afnan Tariq, MD, discusses early data on a passive, device-agnostic AI platform for heart failure monitoring. “When clinicians are empowered with insights and able to act earlier, you're able to have a durable impact," he said.
Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.
ACC.23 Program Chair Doug Drachman, MD, explains what he saw as some of the key takeaways from the American College of Cardiology (ACC) 2023 annual meeting.
Sahil Parikh, MD, talked to Cardiovascular Business about growing trends related to the treatment of critical lower limb ischemia. "We are getting better and better at saving their limbs, but we are not better at saving their lives," he said.
Incoming 2023-2024 American College of Cardiology president Hadley Wilson, MD, shared insights on how to create health equity through grassroots community outreach programs.
Sahil Parikh, MD, director of endovascular services at Columbia University Irving Medical Center, said treating these patients can be quite challenging.
Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.
